Skip to main content
Erschienen in: Journal of Bone and Mineral Metabolism 4/2013

01.07.2013 | Original Article

Cyclic variations of bone resorption mediators and markers in the different phases of the menstrual cycle

verfasst von: Bruno Mozzanega, Salvatore Gizzo, Daniela Bernardi, Luigi Salmaso, Tito Silvio Patrelli, Roberto Mioni, Livio Finos, Giovanni Battista Nardelli

Erschienen in: Journal of Bone and Mineral Metabolism | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Female hormones are very important in regulating bone homeostasis; the drop of estrogen levels occurring at menopause is linked to a dramatic prevalence of bone resorption on formation. Only a small number of studies investigated the relationship between changes in circulating female sex hormones and the markers and mediators of bone homeostasis and they showed conflicting results. To explore such relationships we studied 20 young fertile healthy women, aged between 19 and 32 years. None had received hormone treatment for at least 6 months. We assayed luteinizing hormone, follicle-stimulating hormone, progesterone and 17β-estradiol, as well as the levels of osteoprotegerin (OPG), C-terminal telopeptide of collagen type I (CTx) and RANKL (receptor activator of nuclear factor-B ligand) in samples drawn from every subject at four different times during the menstrual cycle when estrogens are lowest, at the start of the cycle: T 0 (2–4th day); when estrogens are highest, in the pre-ovulatory period: T 14 (12–14th day); when progesterone activity is highest, in the advanced luteal phase: T 26 (24–26th day); and again at the start of the next cycle: T 01 (2–4th day). We observed that CTx levels are highest at the start of the cycle, decreased significantly from T 0 to T 26 (pfwe = 0.0455) and then increased from T 26 to T 01 (pfwe = 0.0415); OPG, on the other hand, which was also highest at the start of the cycle, decreased significantly from T 0 to T 14 (pfwe = 0.02) and then increased, though not significantly, from T 14 to T 01; no variation was observed in RANKL values at any time. We observed inverse correlations between estradiol and OPG levels, which became highly significant at T 01 between estradiol nadir and OPG peak levels (pfw = 0.0095). Furthermore, the increase of estradiol from T 0 to T 14 was negatively correlated with the concomitant decrease of OPG (pfwe = 0.0277), as was the fall of estradiol from T 26 to T 01 with the OPG peak levels, both at T 01 (pfw = 0.0045) and at T 0 (pfwe = 0.0381). We also observed direct correlations between the OPG levels and the variations of progesterone in the preceding intervals, but they never attained statistical significance. We conclude that OPG and CTx fluctuation during the menstrual cycle are likely due to the physiological variations of sex steroids levels.
Literatur
1.
Zurück zum Zitat Gorai I, Taguchi Y, Chaki O, Kikuchi R, Nakayama M, Yang BC, Yokota S, Minaguchi H (1998) Serum soluble interleukin-6 receptor and biochemical markers of bone metabolism show significant variations during the menstrual cycle. J Clin Endocrinol Metab 83:326–332PubMedCrossRef Gorai I, Taguchi Y, Chaki O, Kikuchi R, Nakayama M, Yang BC, Yokota S, Minaguchi H (1998) Serum soluble interleukin-6 receptor and biochemical markers of bone metabolism show significant variations during the menstrual cycle. J Clin Endocrinol Metab 83:326–332PubMedCrossRef
2.
Zurück zum Zitat Chiu KM, Ju J, Mayes D, Bacchetti P, Weitz S, Arnaud CD (1999) Changes in bone resorption during the menstrual cycle. J Bone Miner Res 14:609–615PubMedCrossRef Chiu KM, Ju J, Mayes D, Bacchetti P, Weitz S, Arnaud CD (1999) Changes in bone resorption during the menstrual cycle. J Bone Miner Res 14:609–615PubMedCrossRef
3.
Zurück zum Zitat Zittermann A, Schwarz I, Scheld K, Sudhop T, Berthold HK, von Bergmann K, van der Ven H, Stehle P (2000) Physiologic fluctuations of serum estradiol levels influence biochemical markers of bone resorption in young women. J Clin Endocrinol Metab 85:95–101PubMedCrossRef Zittermann A, Schwarz I, Scheld K, Sudhop T, Berthold HK, von Bergmann K, van der Ven H, Stehle P (2000) Physiologic fluctuations of serum estradiol levels influence biochemical markers of bone resorption in young women. J Clin Endocrinol Metab 85:95–101PubMedCrossRef
4.
Zurück zum Zitat Abrahamsen B, Stilgren LS, Rettmer E, Bonnevie-Nielsen V, Beck-Nielsen H (2003) Effects of the natural and artificial menstrual cycle on the production of osteoprotegerin and the bone resorptive cytokines IL-1beta and IL-6. Calcif Tissue Int 72:18–23PubMedCrossRef Abrahamsen B, Stilgren LS, Rettmer E, Bonnevie-Nielsen V, Beck-Nielsen H (2003) Effects of the natural and artificial menstrual cycle on the production of osteoprotegerin and the bone resorptive cytokines IL-1beta and IL-6. Calcif Tissue Int 72:18–23PubMedCrossRef
5.
Zurück zum Zitat Kato S (2009) Hormones and osteoporosis update. Estrogen and bone remodeling. Clin Calcium 19:951–956PubMed Kato S (2009) Hormones and osteoporosis update. Estrogen and bone remodeling. Clin Calcium 19:951–956PubMed
6.
Zurück zum Zitat Kamel HK (2006) Postmenopausal osteoporosis: etiology, current diagnostic strategies, and nonprescription interventions. J Manag Care Pharm 12:S4–S9PubMed Kamel HK (2006) Postmenopausal osteoporosis: etiology, current diagnostic strategies, and nonprescription interventions. J Manag Care Pharm 12:S4–S9PubMed
7.
Zurück zum Zitat Zallone A (2006) Direct and indirect estrogen actions on osteoblasts and osteoclasts. Ann N Y Acad Sci 1068:173–179PubMedCrossRef Zallone A (2006) Direct and indirect estrogen actions on osteoblasts and osteoclasts. Ann N Y Acad Sci 1068:173–179PubMedCrossRef
8.
Zurück zum Zitat Nielsen HK, Brixen K, Bouillon R, Mosekilde L (1990) Changes in biochemical markers of osteoblastic activity during the menstrual cycle. J Clin Endocrinol Metab 70:1431–1437PubMedCrossRef Nielsen HK, Brixen K, Bouillon R, Mosekilde L (1990) Changes in biochemical markers of osteoblastic activity during the menstrual cycle. J Clin Endocrinol Metab 70:1431–1437PubMedCrossRef
9.
Zurück zum Zitat Mochizuki S, Kiyokawa A, Nagayama Y (2005) Osteoclastogenesis Inhibitory Factor (OCIF)/Osteoprotegerin (OPG) as a new therapeutic agent for osteoporosis. Clin Calcium 15:35–42PubMed Mochizuki S, Kiyokawa A, Nagayama Y (2005) Osteoclastogenesis Inhibitory Factor (OCIF)/Osteoprotegerin (OPG) as a new therapeutic agent for osteoporosis. Clin Calcium 15:35–42PubMed
10.
Zurück zum Zitat Murakami T, Yamamoto M, Ono K, Nishikawa M, Nagata N, Motoyoshi K, Akatsu T (1998) Transforming growth factor-beta1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells. Biochem Biophys Res Commun 252:747–752PubMedCrossRef Murakami T, Yamamoto M, Ono K, Nishikawa M, Nagata N, Motoyoshi K, Akatsu T (1998) Transforming growth factor-beta1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells. Biochem Biophys Res Commun 252:747–752PubMedCrossRef
11.
Zurück zum Zitat Hofbauer LC, Kühne CA, Viereck V (2004) The OPG/RANKL/RANK system in metabolic bone diseases. J Musculoskelet Neuronal Interact 4:268–275PubMed Hofbauer LC, Kühne CA, Viereck V (2004) The OPG/RANKL/RANK system in metabolic bone diseases. J Musculoskelet Neuronal Interact 4:268–275PubMed
12.
Zurück zum Zitat Rachner TD, Schoppet M, Niebergall U, Hofbauer LC (2008) 17beta-Estradiol inhibits osteoprotegerin production by the estrogen receptor-alpha-positive human breast cancer cell line MCF-7. Biochem Biophys Res Commun 368:736–741PubMedCrossRef Rachner TD, Schoppet M, Niebergall U, Hofbauer LC (2008) 17beta-Estradiol inhibits osteoprotegerin production by the estrogen receptor-alpha-positive human breast cancer cell line MCF-7. Biochem Biophys Res Commun 368:736–741PubMedCrossRef
13.
Zurück zum Zitat Rogers A, Eastell R (2005) Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 90:6323–6331PubMedCrossRef Rogers A, Eastell R (2005) Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 90:6323–6331PubMedCrossRef
14.
15.
Zurück zum Zitat Hofbauer LC, Heufelder AE (2000) Clinical review 114: hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. J Clin Endocrinol Metab 85:2355–2363PubMedCrossRef Hofbauer LC, Heufelder AE (2000) Clinical review 114: hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. J Clin Endocrinol Metab 85:2355–2363PubMedCrossRef
16.
Zurück zum Zitat Kostenuik PJ, Shalhoub V (2001) Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des 7:613–635PubMedCrossRef Kostenuik PJ, Shalhoub V (2001) Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des 7:613–635PubMedCrossRef
17.
Zurück zum Zitat Stern A, Laughlin GA, Bergstrom J, Barrett-Connor E (2007) The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study. Eur J Endocrinol 156:555–562PubMedCrossRef Stern A, Laughlin GA, Bergstrom J, Barrett-Connor E (2007) The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study. Eur J Endocrinol 156:555–562PubMedCrossRef
18.
Zurück zum Zitat Wolman I, Gal TB, Jaffa AJ (2009) Cervical mucus status can be accurately estimated by transvaginal ultrasound during fertility evaluation. Fertil Steril 92:1165–1167PubMedCrossRef Wolman I, Gal TB, Jaffa AJ (2009) Cervical mucus status can be accurately estimated by transvaginal ultrasound during fertility evaluation. Fertil Steril 92:1165–1167PubMedCrossRef
19.
Zurück zum Zitat Lee J, Vasikaran S (2012) Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis. Ann Lab Med 32:105–112PubMedCrossRef Lee J, Vasikaran S (2012) Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis. Ann Lab Med 32:105–112PubMedCrossRef
20.
Zurück zum Zitat Di Carlo C, Tommaselli GA, Gargano V, Sammartino A, Bifulco G, Tauchmanova L, Colao A, Nappi C (2007) Effects of estrogen-progestin therapy on serum levels of RANKL, osteoprotegerin, osteocalcin, leptin, and ghrelin in postmenopausal women. Menopause 14:38–44PubMedCrossRef Di Carlo C, Tommaselli GA, Gargano V, Sammartino A, Bifulco G, Tauchmanova L, Colao A, Nappi C (2007) Effects of estrogen-progestin therapy on serum levels of RANKL, osteoprotegerin, osteocalcin, leptin, and ghrelin in postmenopausal women. Menopause 14:38–44PubMedCrossRef
21.
Zurück zum Zitat Salmaso L, Solari A (2005) Multiple aspect testing for case-control designs. Metrika 62:331–340CrossRef Salmaso L, Solari A (2005) Multiple aspect testing for case-control designs. Metrika 62:331–340CrossRef
22.
Zurück zum Zitat Finos L, Salmaso L, Solari A (2007) Conditional inference under simultaneous stochastic ordering constraints. J Stat Plan Inference 137:2633–2641CrossRef Finos L, Salmaso L, Solari A (2007) Conditional inference under simultaneous stochastic ordering constraints. J Stat Plan Inference 137:2633–2641CrossRef
23.
Zurück zum Zitat Corain L, Salmaso L (2004) Multivariate and multistrata nonparametric tests: the nonparametric combination method. J Modern Appl Stat Methods 3:443–461 Corain L, Salmaso L (2004) Multivariate and multistrata nonparametric tests: the nonparametric combination method. J Modern Appl Stat Methods 3:443–461
24.
Zurück zum Zitat Pesarin F (2002) Extending permutation conditional inference to unconditional ones. Stat Methods Appl 11:161–173CrossRef Pesarin F (2002) Extending permutation conditional inference to unconditional ones. Stat Methods Appl 11:161–173CrossRef
25.
Zurück zum Zitat Finos L, Salmaso L (2006) Weighted methods controlling the multiplicity when the number of variables is much higher than the number of observations. J Nonparametr Stat 18:245–261CrossRef Finos L, Salmaso L (2006) Weighted methods controlling the multiplicity when the number of variables is much higher than the number of observations. J Nonparametr Stat 18:245–261CrossRef
26.
Zurück zum Zitat Pesarin F (2001) Multivariate permutation test with applications in biostatistics. Wiley, Chichester, pp 143–150 Pesarin F (2001) Multivariate permutation test with applications in biostatistics. Wiley, Chichester, pp 143–150
27.
Zurück zum Zitat Rickard DJ, Waters KM, Ruesink TJ, Khosla S, Katzenellenbogen JA, Katzenellenbogen BS, Riggs BL, Spelsberg TC (2002) Estrogen receptor isoform-specific induction of progesterone receptors in human osteoblasts. J Bone Miner Res 17:580–592PubMedCrossRef Rickard DJ, Waters KM, Ruesink TJ, Khosla S, Katzenellenbogen JA, Katzenellenbogen BS, Riggs BL, Spelsberg TC (2002) Estrogen receptor isoform-specific induction of progesterone receptors in human osteoblasts. J Bone Miner Res 17:580–592PubMedCrossRef
28.
Zurück zum Zitat Viereck V, Gründker C, Friess SC, Frosch KH, Raddatz D, Schoppet M, Nisslein T, Emons G, Hofbauer LC (2005) Isopropanolic extract of black cohosh stimulates osteoprotegerin production by human osteoblasts. J Bone Miner Res 20:2036–2043PubMedCrossRef Viereck V, Gründker C, Friess SC, Frosch KH, Raddatz D, Schoppet M, Nisslein T, Emons G, Hofbauer LC (2005) Isopropanolic extract of black cohosh stimulates osteoprotegerin production by human osteoblasts. J Bone Miner Res 20:2036–2043PubMedCrossRef
29.
Zurück zum Zitat West SL, Scheid JL, De Souza MJ (2009) The effect of exercise and estrogen on osteoprotegerin in premenopausal women. Bone 44:137–144PubMedCrossRef West SL, Scheid JL, De Souza MJ (2009) The effect of exercise and estrogen on osteoprotegerin in premenopausal women. Bone 44:137–144PubMedCrossRef
30.
Zurück zum Zitat Bord S, Ireland DC, Beavan SR, Compston JE (2003) The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. Bone 32:136–141PubMedCrossRef Bord S, Ireland DC, Beavan SR, Compston JE (2003) The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. Bone 32:136–141PubMedCrossRef
31.
Zurück zum Zitat Rumpler M, Vagra F, Nemeth P, Klaushofer K (2003) Identification of an estrogen response element in the osteoprotegerin promoter. International Conference on Progress in Bone and Mineral Research 2003. Abstracts. Bone 33: S1–S29 Rumpler M, Vagra F, Nemeth P, Klaushofer K (2003) Identification of an estrogen response element in the osteoprotegerin promoter. International Conference on Progress in Bone and Mineral Research 2003. Abstracts. Bone 33: S1–S29
32.
Zurück zum Zitat Viereck V, Gründker C, Blaschke S, Niederkleine B, Siggelkow H, Frosch KH, Raddatz D, Emons G, Hofbauer LC (2003) Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. J Clin Endocrinol Metab 88:4206–4213PubMedCrossRef Viereck V, Gründker C, Blaschke S, Niederkleine B, Siggelkow H, Frosch KH, Raddatz D, Emons G, Hofbauer LC (2003) Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. J Clin Endocrinol Metab 88:4206–4213PubMedCrossRef
33.
Zurück zum Zitat Hofbauer LC, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S (1998) Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun 250:776–781PubMedCrossRef Hofbauer LC, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S (1998) Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun 250:776–781PubMedCrossRef
34.
Zurück zum Zitat Brändström H, Jonsson KB, Vidal O, Ljunghall S, Ohlsson C, Ljunggren O (1998) Tumor necrosis factor-alpha and -beta upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells. Biochem Biophys Res Commun 248:454–457PubMedCrossRef Brändström H, Jonsson KB, Vidal O, Ljunghall S, Ohlsson C, Ljunggren O (1998) Tumor necrosis factor-alpha and -beta upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells. Biochem Biophys Res Commun 248:454–457PubMedCrossRef
35.
Zurück zum Zitat Riggs BL, Khosla S, Melton LJ 3rd (2002) Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 23:279–302PubMedCrossRef Riggs BL, Khosla S, Melton LJ 3rd (2002) Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 23:279–302PubMedCrossRef
36.
Zurück zum Zitat Inada M, Miyaura C (2010) Cytokines in bone diseases. Cytokine and postmenopausal Osteoporosis. Clin Calcium 20:1467–1472PubMed Inada M, Miyaura C (2010) Cytokines in bone diseases. Cytokine and postmenopausal Osteoporosis. Clin Calcium 20:1467–1472PubMed
37.
Zurück zum Zitat Jilka RL (2003) Biology of the basic multicellular unit and the pathophysiology of osteoporosis. Med Pediatr Oncol 41:182–185PubMedCrossRef Jilka RL (2003) Biology of the basic multicellular unit and the pathophysiology of osteoporosis. Med Pediatr Oncol 41:182–185PubMedCrossRef
38.
Zurück zum Zitat Bashir A, Mak YT, Sankaralingam S, Cheung J, McGowan NW, Grigoriadis AE, Fogelman I, Hampson G (2005) Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene. Steroids 70:847–855PubMedCrossRef Bashir A, Mak YT, Sankaralingam S, Cheung J, McGowan NW, Grigoriadis AE, Fogelman I, Hampson G (2005) Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene. Steroids 70:847–855PubMedCrossRef
39.
Zurück zum Zitat Rachner TD, Schoppet M, Niebergall U, Hofbauer LC (2008) 17beta-Estradiol inhibits osteoprotegerin production by the estrogen receptor-alpha-positive human breast cancer cell line MCF-7. Biochem Biophys Res Commun 368:736–741PubMedCrossRef Rachner TD, Schoppet M, Niebergall U, Hofbauer LC (2008) 17beta-Estradiol inhibits osteoprotegerin production by the estrogen receptor-alpha-positive human breast cancer cell line MCF-7. Biochem Biophys Res Commun 368:736–741PubMedCrossRef
40.
Zurück zum Zitat Ohwada R, Hotta M, Sato K, Shibasaki T, Takano K (2007) The relationship between serum levels of estradiol and osteoprotegerin in patients with anorexia nervosa. Endocr J 54:953–959PubMedCrossRef Ohwada R, Hotta M, Sato K, Shibasaki T, Takano K (2007) The relationship between serum levels of estradiol and osteoprotegerin in patients with anorexia nervosa. Endocr J 54:953–959PubMedCrossRef
41.
Zurück zum Zitat Kim JG, Kim JH, Lee DO, Kim H, Kim JY, Suh CS, Kim SH, Choi YM (2008) Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women. Menopause 15:357–362PubMedCrossRef Kim JG, Kim JH, Lee DO, Kim H, Kim JY, Suh CS, Kim SH, Choi YM (2008) Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women. Menopause 15:357–362PubMedCrossRef
42.
Zurück zum Zitat Indridason OS, Franzson L, Sigurdsson G (2005) Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. Osteoporos Int 16:417–423PubMedCrossRef Indridason OS, Franzson L, Sigurdsson G (2005) Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. Osteoporos Int 16:417–423PubMedCrossRef
43.
Zurück zum Zitat Liu JM, Zhao HY, Ning G, Zhao YJ, Chen Y, Zhang Zh, Sun LH, Xu MY, Chen JL (2005) Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20–75. Calcif Tissue Int 76:1–6PubMedCrossRef Liu JM, Zhao HY, Ning G, Zhao YJ, Chen Y, Zhang Zh, Sun LH, Xu MY, Chen JL (2005) Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20–75. Calcif Tissue Int 76:1–6PubMedCrossRef
44.
Zurück zum Zitat Hofbauer LC, Schoppet M, Schüller P, Viereck V, Christ M (2004) Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women. Clin Endocrinol (Oxf) 60:214–219CrossRef Hofbauer LC, Schoppet M, Schüller P, Viereck V, Christ M (2004) Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women. Clin Endocrinol (Oxf) 60:214–219CrossRef
45.
Zurück zum Zitat The Writing Group for the PEPI (1996) Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 276:1389–1396CrossRef The Writing Group for the PEPI (1996) Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 276:1389–1396CrossRef
Metadaten
Titel
Cyclic variations of bone resorption mediators and markers in the different phases of the menstrual cycle
verfasst von
Bruno Mozzanega
Salvatore Gizzo
Daniela Bernardi
Luigi Salmaso
Tito Silvio Patrelli
Roberto Mioni
Livio Finos
Giovanni Battista Nardelli
Publikationsdatum
01.07.2013
Verlag
Springer Japan
Erschienen in
Journal of Bone and Mineral Metabolism / Ausgabe 4/2013
Print ISSN: 0914-8779
Elektronische ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-013-0430-4

Weitere Artikel der Ausgabe 4/2013

Journal of Bone and Mineral Metabolism 4/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.